Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically ...
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- ...
Parasitologist and director of the Wellcome Trust who oversaw the launch of the UK’s flagship genome sequencing centre ...
Database could be used to regulate opponents, from ‘shutting off bank accounts’ to healthcare, official warns ...
After the rofecoxib (Vioxx) withdrawal in 2004 made painfully clear how much harm a passive reporting system can miss, ...
Nara Fry is happiest when moving to the beat of music. The seven-year-old loves nothing more than her dance or gymnastics ...
RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Administering RSV and shingles vaccines simultaneously in older adults appears to be safe and does not compromise immune ...
11d
Krystal Biotech, Inc.: Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results